The 2021 Surviving Sepsis Campaign guideline provides a broad evidence-based framework for managing adults with sepsis and septic shock. It emphasises rapid recognition, prompt antimicrobial therapy when indicated, early source control, appropriate intravenous crystalloid resuscitation and vasopressor support when hypotension persists. The guideline favours balanced crystalloids over saline in many patients and recommends norepinephrine as the first-line vasopressor, with additional agents considered when adequate arterial pressure is not achieved. It also moves away from treating a fixed protocol as the goal of resuscitation, instead encouraging repeated clinical assessment and individualisation of fluids and haemodynamic therapy. Beyond the initial hours, the document addresses ventilation, corticosteroids, renal replacement, glucose management, nutrition, infection control and post-ICU care. Importantly, the recommendations are graded according to the certainty of available evidence, and many familiar ICU practices remain areas of uncertainty. For clinicians, the value of the guideline is not simply a bundle of actions but a structured approach that links rapid treatment with reassessment, stewardship and attention to adverse effects. It also underscores that sepsis care must be adapted to patient physiology rather than delivered as a rigid one-size-fits-all protocol.